Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period

IF 3.6 2区医学 Q1 PSYCHIATRY

Drug and alcohol dependence Pub Date : 2025-10-10 DOI:10.1016/j.drugalcdep.2025.112917

Christina L. Redondo , Bente Weimand , Jūratė Šaltytė Benth , John-Kåre Vederhus , Jon Mordal , Asle Enger , Lars Tanum , Kristin Klemmetsby Solli

{"title":"Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period","authors":"Christina L. Redondo , Bente Weimand , Jūratė Šaltytė Benth , John-Kåre Vederhus , Jon Mordal , Asle Enger , Lars Tanum , Kristin Klemmetsby Solli","doi":"10.1016/j.drugalcdep.2025.112917","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study investigates changes in quality of life (QoL) among individuals with opioid use disorder (OUD) undergoing extended-release naltrexone (XR-NTX) treatment for 52 weeks, subsequent by a 1-year post-treatment period.</div></div><div><h3>Methods</h3><div>Conducted as a naturalistic, multicenter, open-label clinical trial across five urban hospitals in southern Norway, this observational study enrolled 158 participants with severe OUD. Participants received XR-NTX treatment for up to 52 weeks, with QoL assessed using the WHOQOL-BREF instrument at five time points during treatment and twice during the post-treatment period. The Addiction Severity Index, European version (EuropASI) was used to measure covariates. A linear mixed model was employed to analyze trends in QoL, adjusting for mental distress severity and substance use severity.</div></div><div><h3>Results</h3><div>Significant improvements in QoL were observed in the physical, psychological, social and environmental domains during the XR-NTX treatment, with less pronounced changes in the environmental domain. Mental distress and substance use severity were negatively associated with QoL scores. The most substantial QoL improvements occurred within the first year of treatment, with overall perceived QoL remaining stable during the 1-year post-treatment period.</div></div><div><h3>Conclusions</h3><div>This study highlights XR-NTX as a beneficial treatment option for enhancing QoL in individuals with OUD. The findings support the integration of XR-NTX into OUD treatment plans and emphasize the need for further research to explore long-term outcomes and the impact of external factors on QoL.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"276 ","pages":"Article 112917"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871625003709","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This study investigates changes in quality of life (QoL) among individuals with opioid use disorder (OUD) undergoing extended-release naltrexone (XR-NTX) treatment for 52 weeks, subsequent by a 1-year post-treatment period.

Methods

Conducted as a naturalistic, multicenter, open-label clinical trial across five urban hospitals in southern Norway, this observational study enrolled 158 participants with severe OUD. Participants received XR-NTX treatment for up to 52 weeks, with QoL assessed using the WHOQOL-BREF instrument at five time points during treatment and twice during the post-treatment period. The Addiction Severity Index, European version (EuropASI) was used to measure covariates. A linear mixed model was employed to analyze trends in QoL, adjusting for mental distress severity and substance use severity.

Results

Significant improvements in QoL were observed in the physical, psychological, social and environmental domains during the XR-NTX treatment, with less pronounced changes in the environmental domain. Mental distress and substance use severity were negatively associated with QoL scores. The most substantial QoL improvements occurred within the first year of treatment, with overall perceived QoL remaining stable during the 1-year post-treatment period.

Conclusions

This study highlights XR-NTX as a beneficial treatment option for enhancing QoL in individuals with OUD. The findings support the integration of XR-NTX into OUD treatment plans and emphasize the need for further research to explore long-term outcomes and the impact of external factors on QoL.

查看原文本刊更多论文

52周纳曲酮缓释治疗期间生活质量的变化，随后是1年的治疗后期。

背景：本研究调查了阿片类药物使用障碍（OUD）患者接受52周缓释纳曲酮（XR-NTX）治疗后1年生活质量（QoL）的变化。方法：作为一项自然、多中心、开放标签的临床试验，在挪威南部的五家城市医院进行了这项观察性研究，纳入了158名严重OUD患者。参与者接受XR-NTX治疗长达52周，在治疗期间的5个时间点和治疗后的2个时间点使用WHOQOL-BREF仪器评估生活质量。使用欧洲版本的成瘾严重程度指数（EuropASI）来测量协变量。采用线性混合模型分析生活质量趋势，调整精神困扰严重程度和物质使用严重程度。结果：XR-NTX治疗期间，患者在生理、心理、社会和环境领域的生活质量均有显著改善，环境领域的变化不明显。精神痛苦和物质使用严重程度与生活质量评分呈负相关。最显著的生活质量改善发生在治疗的第一年，总体感知生活质量在治疗后的一年内保持稳定。结论：本研究强调XR-NTX是提高OUD患者生活质量的有益治疗选择。研究结果支持将XR-NTX纳入OUD治疗计划，并强调需要进一步研究以探索长期结果和外部因素对生活质量的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug and alcohol dependence 医学-精神病学

CiteScore

7.40

自引率

7.10%

发文量

409

审稿时长

41 days

期刊介绍： Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.